8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Therapeutic potential of curcumin in ARDS and COVID‐19

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Curcumin is a safe, non‐toxic, readily available and naturally occurring compound, an active constituent of Curcuma longa (turmeric). Curcumin could potentially treat diseases, but faces poor physicochemical and pharmacological characteristics. To overcome these limitations, we developed a stable, water‐soluble formulation of curcumin called cyclodextrin‐complexed curcumin (CDC). We have previously shown that direct delivery of CDC to the lung following lipopolysaccharides exposure reduces acute lung injury (ALI) and effectively reduces lung injury, inflammation and mortality in mice following Klebsiella pneumoniae. Recently, we found that administration of CDC led to a significant reduction in angiotensin‐converting enzyme 2 and signal transducer and activator of transcription 3 expression in gene and protein levels following pneumonia, indicating its potential in treating coronavirus disease 2019 (COVID‐19). In this review, we consider the clinical features of ALI and acute respiratory distress syndrome (ARDS) and the role of curcumin in modulating the pathogenesis of bacterial/viral‐induced ARDS and COVID‐19.

          Abstract

          The schematics represent the potential mechanisms by which CDC effectively protects against ARDS/COVID‐19. Antiviral curcumin against SARS‐CoV‐2 mediated by distracting the ACE2, which prevents the entry of the virus into the cells. CDC induces antiviral responses by positively repressing the expression of ACE2, Nrf2, STAT‐3 and C–X–C motif chemokine 10 (CXCL10). CDC mediates immunomodulatory responses by inhibiting inflammation, cytokines, apoptosis and oxidative stress, therefore mitigating the progression to KP/ARDS following SARS‐CoV‐2 infection. CDC, cyclodextrin‐complexed curcumin; ARDS, acute respiratory distress syndrome; coronavirus disease 2019, COVID‐19; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; ACE2, angiotensin‐converting enzyme 2; Nrf2, nuclear factor erythroid 2 related factor 2; STAT‐3, signal transducer and activator of transcription 3; KP, Klebsiella pneumoniae

          Related collections

          Most cited references107

          • Record: found
          • Abstract: found
          • Article: found

          Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

            Structure of the nCoV trimeric spike The World Health Organization has declared the outbreak of a novel coronavirus (2019-nCoV) to be a public health emergency of international concern. The virus binds to host cells through its trimeric spike glycoprotein, making this protein a key target for potential therapies and diagnostics. Wrapp et al. determined a 3.5-angstrom-resolution structure of the 2019-nCoV trimeric spike protein by cryo–electron microscopy. Using biophysical assays, the authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor. They also tested three antibodies known to bind to the SARS-CoV spike protein but did not detect binding to the 2019-nCoV spike protein. These studies provide valuable information to guide the development of medical counter-measures for 2019-nCoV. Science, this issue p. 1260
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

              Journal of Clinical Investigation
                Bookmark

                Author and article information

                Contributors
                madathil@umich.edu
                Journal
                Clin Exp Pharmacol Physiol
                Clin Exp Pharmacol Physiol
                10.1111/(ISSN)1440-1681
                CEP
                Clinical and Experimental Pharmacology & Physiology
                John Wiley and Sons Inc. (Hoboken )
                0305-1870
                1440-1681
                10 January 2023
                10 January 2023
                : 10.1111/1440-1681.13744
                Affiliations
                [ 1 ] Department of Surgery University of Michigan Ann Arbor Michigan USA
                Author notes
                [*] [* ] Correspondence

                Suresh Madathilparambil, Department of Surgery, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, Michigan, 48109, USA.

                Email: madathil@ 123456umich.edu

                Article
                CEP13744
                10.1111/1440-1681.13744
                9877870
                36480131
                6ed7f4ea-940a-49e0-8852-6c06aea8665a
                © 2022 John Wiley & Sons Australia, Ltd.

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                : 13 November 2022
                : 10 August 2022
                : 30 November 2022
                Page count
                Figures: 2, Tables: 0, Pages: 10, Words: 9662
                Funding
                Funded by: National Institutes of Health , doi 10.13039/100000002;
                Award ID: HL102013
                Categories
                Review
                Reviews
                Custom metadata
                2.0
                corrected-proof
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.4 mode:remove_FC converted:26.01.2023

                Pharmacology & Pharmaceutical medicine
                ali,ards,covid‐19,curcumin,nf‐κb,pneumonia
                Pharmacology & Pharmaceutical medicine
                ali, ards, covid‐19, curcumin, nf‐κb, pneumonia

                Comments

                Comment on this article